Isaac Barchas
Director/Board Member at IMMUNOME, INC.
Net worth: 2 M $ as of 30/04/2024
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Ronald Martell | M | 62 |
MorphImmune, Inc.
 MorphImmune, Inc. BiotechnologyHealth Technology MorphImmune, Inc. is a biotechnology company that specializes in developing targeted oncology therapeutics. MorphImmune is based in West Lafayette, IN and has been led by CEO Clay B. Siegall since 2023. The company's proprietary targeted effector platform delivers payloads to diseased cells, reducing toxicity and increasing efficacy of known effector molecules. The company was founded on the research of Philip S. Low, Ph.D., the Presidential Scholar for Drug Discovery and Ralph C. Corley Distinguished Professor of Chemistry at Purdue University. | 3 years |
| Max Rosett | M | 34 |
Research Bridge Partners /Venture Capital/
 Research Bridge Partners /Venture Capital/ Investment ManagersFinance Research Bridge Partners (Research Bridge Partners) is a venture capital firm founded in 2016 by Reid Hoffman. The firm is headquartered in Austin, Texas. | 6 years |
| Philip Low | M | 76 |
Novosteo, Inc.
 Novosteo, Inc. Pharmaceuticals: MajorHealth Technology Novosteo, Inc. develops drug to reduce complications from a broken bone. The company was founded by Stewart A. Low and Philips S. Low in 2017 and is headquartered in West Lafayette, IN.
MorphImmune, Inc.
MorphImmune, Inc. BiotechnologyHealth Technology MorphImmune, Inc. is a biotechnology company that specializes in developing targeted oncology therapeutics. MorphImmune is based in West Lafayette, IN and has been led by CEO Clay B. Siegall since 2023. The company's proprietary targeted effector platform delivers payloads to diseased cells, reducing toxicity and increasing efficacy of known effector molecules. The company was founded on the research of Philip S. Low, Ph.D., the Presidential Scholar for Drug Discovery and Ralph C. Corley Distinguished Professor of Chemistry at Purdue University. | - |
| Lindsay Dow | F | - |
Research Bridge Partners /Venture Capital/
Research Bridge Partners /Venture Capital/ Investment ManagersFinance Research Bridge Partners (Research Bridge Partners) is a venture capital firm founded in 2016 by Reid Hoffman. The firm is headquartered in Austin, Texas.
Tetricus Labs
 Tetricus Labs Packaged SoftwareTechnology Services Tetricus Labs is a company that develops a platform for patients to manage their own care. The company is based in New Haven, NY. The company was founded in 2022 by Sean McCurdy, Phil Corlett, Lindsay Dow. Lindsay Dow has been the CEO since 2022. | 2 years |
| Franklyn Prendergast | M | 79 |
Novosteo, Inc.
Novosteo, Inc. Pharmaceuticals: MajorHealth Technology Novosteo, Inc. develops drug to reduce complications from a broken bone. The company was founded by Stewart A. Low and Philips S. Low in 2017 and is headquartered in West Lafayette, IN.
MorphImmune, Inc.
MorphImmune, Inc. BiotechnologyHealth Technology MorphImmune, Inc. is a biotechnology company that specializes in developing targeted oncology therapeutics. MorphImmune is based in West Lafayette, IN and has been led by CEO Clay B. Siegall since 2023. The company's proprietary targeted effector platform delivers payloads to diseased cells, reducing toxicity and increasing efficacy of known effector molecules. The company was founded on the research of Philip S. Low, Ph.D., the Presidential Scholar for Drug Discovery and Ralph C. Corley Distinguished Professor of Chemistry at Purdue University. | 4 years |
| Sunil Singhal | M | - |
Research Bridge Partners /Venture Capital/
Research Bridge Partners /Venture Capital/ Investment ManagersFinance Research Bridge Partners (Research Bridge Partners) is a venture capital firm founded in 2016 by Reid Hoffman. The firm is headquartered in Austin, Texas.
MorphImmune, Inc.
MorphImmune, Inc. BiotechnologyHealth Technology MorphImmune, Inc. is a biotechnology company that specializes in developing targeted oncology therapeutics. MorphImmune is based in West Lafayette, IN and has been led by CEO Clay B. Siegall since 2023. The company's proprietary targeted effector platform delivers payloads to diseased cells, reducing toxicity and increasing efficacy of known effector molecules. The company was founded on the research of Philip S. Low, Ph.D., the Presidential Scholar for Drug Discovery and Ralph C. Corley Distinguished Professor of Chemistry at Purdue University. | 4 years |
| Clay Siegall | M | 63 | 1 years | |
| Sandra Stoneman | F | 51 | 4 years | |
| Sean McCurdy | M | - |
Tetricus Labs
Tetricus Labs Packaged SoftwareTechnology Services Tetricus Labs is a company that develops a platform for patients to manage their own care. The company is based in New Haven, NY. The company was founded in 2022 by Sean McCurdy, Phil Corlett, Lindsay Dow. Lindsay Dow has been the CEO since 2022. | 2 years |
| Phil Corlett | M | - |
Tetricus Labs
Tetricus Labs Packaged SoftwareTechnology Services Tetricus Labs is a company that develops a platform for patients to manage their own care. The company is based in New Haven, NY. The company was founded in 2022 by Sean McCurdy, Phil Corlett, Lindsay Dow. Lindsay Dow has been the CEO since 2022. | 2 years |
| Stewart A. Low | M | - |
Novosteo, Inc.
Novosteo, Inc. Pharmaceuticals: MajorHealth Technology Novosteo, Inc. develops drug to reduce complications from a broken bone. The company was founded by Stewart A. Low and Philips S. Low in 2017 and is headquartered in West Lafayette, IN. | - |
| Daniel Hasler | M | 66 |
Novosteo, Inc.
Novosteo, Inc. Pharmaceuticals: MajorHealth Technology Novosteo, Inc. develops drug to reduce complications from a broken bone. The company was founded by Stewart A. Low and Philips S. Low in 2017 and is headquartered in West Lafayette, IN. | - |
| Matthew Robinson | M | 55 | 8 years | |
| Philip Wagenheim | M | 53 | 7 years | |
| John M. Cioffi | M | 66 |
Stanford University
| 38 years |
| John Howard | M | 63 |
Stanford University
| 35 years |
| Kinney Horn | M | 49 | - | |
| Bruce Turner | M | 60 | 1 years | |
| Brendan Hannah | M | 39 |
Novosteo, Inc.
Novosteo, Inc. Pharmaceuticals: MajorHealth Technology Novosteo, Inc. develops drug to reduce complications from a broken bone. The company was founded by Stewart A. Low and Philips S. Low in 2017 and is headquartered in West Lafayette, IN. | - |
| Lydia McClure | F | - |
Research Bridge Partners /Venture Capital/
Research Bridge Partners /Venture Capital/ Investment ManagersFinance Research Bridge Partners (Research Bridge Partners) is a venture capital firm founded in 2016 by Reid Hoffman. The firm is headquartered in Austin, Texas. | 7 years |
| Alex Andrianopoulos | M | - |
Novosteo, Inc.
Novosteo, Inc. Pharmaceuticals: MajorHealth Technology Novosteo, Inc. develops drug to reduce complications from a broken bone. The company was founded by Stewart A. Low and Philips S. Low in 2017 and is headquartered in West Lafayette, IN. | - |
| James Boylan | M | 57 | 1 years | |
| Karen Smith | M | 56 |
Novosteo, Inc.
Novosteo, Inc. Pharmaceuticals: MajorHealth Technology Novosteo, Inc. develops drug to reduce complications from a broken bone. The company was founded by Stewart A. Low and Philips S. Low in 2017 and is headquartered in West Lafayette, IN. | - |
| Jack Higgins | M | 45 | 1 years | |
| George Cloyd | M | 78 |
Research Bridge Partners /Venture Capital/
Research Bridge Partners /Venture Capital/ Investment ManagersFinance Research Bridge Partners (Research Bridge Partners) is a venture capital firm founded in 2016 by Reid Hoffman. The firm is headquartered in Austin, Texas. | 7 years |
| Jack P. Dvorkin | M | - |
Stanford University
| 35 years |
| Jim Graham | M | - |
Research Bridge Partners /Venture Capital/
Research Bridge Partners /Venture Capital/ Investment ManagersFinance Research Bridge Partners (Research Bridge Partners) is a venture capital firm founded in 2016 by Reid Hoffman. The firm is headquartered in Austin, Texas. | 7 years |
| John Howard | M | - |
Stanford University
| 35 years |
| Monica Sin-Ling Lam | M | - |
Stanford University
| 36 years |
| Thomas Charles Merigan | M | 90 |
Stanford University
| 36 years |
| Irving L. Weissman | M | 84 |
Stanford University
| 35 years |
| Jean-Jacques Bienaimé | M | 70 | 1 years | |
| William J. Rutter | M | - |
Novosteo, Inc.
Novosteo, Inc. Pharmaceuticals: MajorHealth Technology Novosteo, Inc. develops drug to reduce complications from a broken bone. The company was founded by Stewart A. Low and Philips S. Low in 2017 and is headquartered in West Lafayette, IN. | - |
| Siu-Weng Wong | M | 69 |
Stanford University
| 36 years |
| Stephen J. Smith | M | 78 |
Stanford University
| 35 years |
| Peter D. O'Hanley | M | 73 |
Stanford University
| 39 years |
| Carol Schafer | F | 60 | - | |
| Bob Lechleider | M | 63 | 1 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Purnanand Sarma | M | 59 | 4 years | |
| Jorge Titinger | M | 62 |
Stanford University
| 7 years |
| Corleen Roche | F | 58 | 3 years | |
| Raj Atluru | M | 54 |
Stanford University
| 10 years |
| Mani Sadeghi | M | 60 |
Stanford University
| 4 years |
| Robert Brown | M | - |
Stanford University
| 5 years |
| Mark Sander | M | 68 |
Stanford University
| 10 years |
| Geoff S. Keith | M | - |
Stanford University
| 5 years |
| Tobin C. Island | M | 57 |
Stanford University
| 5 years |
| Jeffrey Bede | M | - |
Stanford University
| 4 years |
| David Tony Lillios | M | - |
Stanford University
| 5 years |
| Chris Jones | M | 56 |
Stanford University
| 5 years |
| Gregory Malcom Tusher | M | - |
Stanford University
| 10 years |
| Linda Ginsburg | F | - |
Stanford University
| 5 years |
| Nasser Mustafa Mohamed Saad Khraishi | M | 62 |
Stanford University
| 5 years |
| Erik Falk | M | 54 |
Stanford University
| 4 years |
| Larry Alder | M | - |
Stanford University
| 6 years |
| Mohammad Ali Hassan Mohammad Ikwan | M | - |
Stanford University
| 3 years |
| John D. Knoll | M | 52 |
Stanford University
| 11 years |
| Mark V. Matthews | M | - |
Stanford University
| 6 years |
| Michael Lefenfeld | M | 43 | 6 years | |
| Ashley Johnson | F | 52 |
Stanford University
| 6 years |
| Christopher Petti | M | - |
Stanford University
| 7 years |
| Stephen Fisher | M | 60 |
Stanford University
| 5 years |
| Martin A. Fischer | M | 64 |
Stanford University
| 5 years |
| Ashwin Bulchandani | M | - |
Stanford University
| 5 years |
| Eric Johnson | M | - |
Stanford University
| 10 years |
| Jane Woodward | F | 64 |
Stanford University
| 7 years |
| Susan Bryenton | F | - |
Stanford University
| 5 years |
| H. C Ursula Keller | M | 65 |
Stanford University
| 3 years |
| Robert Kalman | M | - |
Stanford University
| 6 years |
| Rob Romero | M | - |
Stanford University
| 5 years |
| Michelangelo Volpi | M | 57 |
Stanford University
| 5 years |
| Tzar Kuoi Li | M | 59 |
Stanford University
| 4 years |
| Michael L. Ehrman | M | 50 |
Stanford University
| 5 years |
| David ibnAle | M | 52 |
Stanford University
| 5 years |
| Aron B. Anderson | M | 60 |
Stanford University
| 5 years |
| Stelleo Tolda | M | 55 |
Stanford University
| 5 years |
| Steve Jurvetson | M | 57 |
Stanford University
| 5 years |
| Blake Grossman | M | 61 |
Stanford University
| 5 years |
| Bradley Robert Kent | M | - |
Stanford University
| 5 years |
| Rapp Rapoport | M | 56 | 8 years | |
| Kenneth McBride | M | 56 |
Stanford University
| 6 years |
| William Staib | M | - |
Stanford University
| 4 years |
| Selena Chaisson | M | - |
Stanford University
| 5 years |
| John LaMattina | M | 74 | 6 years | |
| Steven C. Voorhis | M | - |
Stanford University
| 4 years |
| Penny Pritzker | F | 65 |
Stanford University
| - |
| Charles J. Jacklin | M | 69 |
Stanford University
| 10 years |
| Ryan A. Harris | M | - |
Stanford University
| 6 years |
| Tim D. Keyes | M | - |
Stanford University
| 8 years |
| Richard Baron | M | 68 | 3 years | |
| Jeff T. Soukup | M | 58 |
Stanford University
| 4 years |
| Trevor Loy | M | - |
Stanford University
| 10 years |
| Andrew R. Garman | M | 65 |
Stanford University
| 7 years |
| Jim Chung | M | - |
Stanford University
| 5 years |
| Jon Staenberg | M | - |
Stanford University
| 10 years |
| Samer Hamadeh | M | - |
Stanford University
| 5 years |
| Frank Lexa | M | - |
Stanford University
| 4 years |
| M. Robinson | M | - |
Stanford University
| 5 years |
| J. B. Holston | M | - |
Stanford University
| 3 years |
| Ahmed Farooq | M | - |
Stanford University
| 6 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 100 | 100.00% |
| Cayman Islands | 0 | -.--% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Isaac Barchas
- Personal Network
